Bronchoscopic airway clearance therapy for acute exacerbations of bronchiectasis.

ABSTRACT:

Background

Persistent cough and large amounts of purulent sputum affects many bronchiectasis patients. No studies have evaluated the efficacy and safety of bronchoscopic airway clearance therapy and bronchoalveolar lavage (B-ACT) for non-cystic fibrosis bronchiectasis patients with acute exacerbation.

Methods

A randomised controlled trial was conducted to explore the efficacy and safety of B-ACT among 189 bronchiectasis inpatients from February 1, 2018 to February 28, 2019. The primary outcome was the time to first acute exacerbation. Secondary outcomes included changes of health-related scores, length of hospital stay, hospitalization expenses and incidences of adverse events.

Findings

B-ACT therapy significantly prolonged the median days to first acute exacerbation

SUBMITTER: Liu Y 

PROVIDER: S-EPMC8452777 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature